Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Notice of Proposed Sale · 144

Jazz Pharmaceuticals plc

JAZZNASDAQEQUITYCurrent

Notice of Proposed Sale

Filed Aug 31, 2026Accepted Aug 31, 2026, 3:10 PM EDTFiling CIK 1232524Accession 0001193210-26-000023
Share

Structured filing — 144

primary_doc.xml

Open full document ↗

Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.

Proposed-sale notice

Issuer
Jazz Pharmaceuticals plc
Issuer CIK
0001232524
SEC file number
001-33500
Phone
353-1-634-7800
Person for whose account securities are to be sold
COZADD BRUCE C
Relationships to issuer
Director
Street
FIFTH FLOOR, WATERLOO EXCHANGE
Street (continued)
WATERLOO ROAD
City
DUBLIN
State / country code
L2
Postal code
D04 E5W7

Securities proposed for sale

Securities proposed for sale · 1 reported row
SecurityProposed unitsAggregate market valueUnits outstandingApproximate sale dateExchangeBroker / market maker
Common2,506612,817.0064,914,57708/31/2026NASDAQETRADE FINANCIAL CORPORATION

Broker / market maker — proposed row 1, entry 1

Name
ETRADE FINANCIAL CORPORATION
Street
3 EDISON DRIVE
City
ALPHARETTA
State / country code
GA
Postal code
30005

Acquisition of securities to be sold

Acquisition of securities to be sold · 1 reported row
SecurityAcquiredNature of acquisitionAcquired fromAmount acquiredGift transactionPayment dateNature of payment
COMMON08/28/2026RESTRICTED STOCK VESTINGISSUER2,506N08/28/2026Compensation

Sales reported in the preceding three months

Sales reported in the preceding three months · 3 reported rows
SellerSecuritySale dateAmount soldGross proceeds
COZADD BRUCE C.COMMON08/03/20266,0001,517,880.00
COZADD BRUCE C.COMMON07/01/20266,0001,442,820.00
COZADD BRUCE C.COMMON06/01/20266,0001,410,720.00

Seller — prior-sale row 1, entry 1

Name
COZADD BRUCE C.
Street
3000 El Camino Real
Street (continued)
2 Palo Alto Square, Suite 600
City
Palo Alto
State / country code
CA
Postal code
94306

Seller — prior-sale row 2, entry 1

Name
COZADD BRUCE C.
Street
3000 El Camino Real
Street (continued)
2 Palo Alto Square, Suite 600
City
Palo Alto
State / country code
CA
Postal code
94306

Seller — prior-sale row 3, entry 1

Name
COZADD BRUCE C.
Street
3000 El Camino Real
Street (continued)
2 Palo Alto Square, Suite 600
City
Palo Alto
State / country code
CA
Postal code
94306

Prior-sale reporting

Nothing to report for the preceding three months
N

Notice signature

Notice date
08/31/2026
Signed
/s/Paz Dizon by power of attorney for Bruce C. Cozadd

Company context

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare diseases - often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide.

Current securities

Recent company filings

  1. Results of Operations and Financial ConditionOct 26, 2026
  2. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsOct 9, 2026
  3. 4 filingOct 5, 2026
  4. 144 filingOct 1, 2026
  5. Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet ArrangementSep 23, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.